OTCMKTS:ENZN Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis $4.35 0.00 (0.00%) As of 09/18/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enzon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.35▼$4.3550-Day Range$4.21▼$4.3952-Week Range$1.50▼$9.50VolumeN/AAverage Volume1,513 shsMarket Capitalization$3.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Enzon Pharmaceuticals, Inc. was a biopharmaceutical company focused on developing and commercializing medicines using its proprietary PEGylation technology. PEGylation attaches polyethylene glycol to therapeutic molecules to potentially extend their time in the body and improve treatment characteristics. The company’s historical product portfolio included ADAGEN (pegademase bovine), a treatment for adenosine deaminase deficiency; ONCASPAR (pegaspargase), used in the treatment of acute lymphoblastic leukemia; and other PEGylated therapies developed independently or with pharmaceutical partners. Enzon also licensed its PEGylation technology to other companies for use in drug development. Enzon was based in Bridgewater, New Jersey, and served the biopharmaceutical and healthcare markets through products and technology partnerships. The company later significantly reduced its operations and pursued strategic alternatives, so historical descriptions of its business may not reflect an active operating pharmaceutical company today.AI Generated. May Contain Errors. Read More Receive ENZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENZN Stock News HeadlinesViskase Holdings (ENZN) RatiosJuly 18, 2026 | uk.investing.comEnzon Pharmaceuticals Amends and Extends Credit Agreement FacilitiesApril 21, 2026 | tipranks.com“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.September 20 at 1:00 AM | Chaikin Analytics (Ad)Enzon Pharmaceuticals Announces New Permanent Financial LeadershipApril 15, 2026 | tipranks.comEnzon Completes Merger and Rebrands as Viskase HoldingsMarch 26, 2026 | tipranks.comEnzon Pharmaceuticals Inc.March 25, 2026 | barrons.comEnzon Pharmaceuticals Completes Exchange Offer for Preferred StockMarch 25, 2026 | tipranks.comEnzon Announces Completion of the Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred StockMarch 25, 2026 | globenewswire.comSee More Headlines ENZN Stock Analysis - Frequently Asked Questions How have ENZN shares performed this year? Enzon Pharmaceuticals' stock was trading at $3.78 at the beginning of 2026. Since then, ENZN stock has increased by 15.1% and is now trading at $4.35. How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) posted its quarterly earnings results on Monday, May, 4th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter. The biotechnology company earned $86.54 million during the quarter. When did Enzon Pharmaceuticals' stock split? Shares of Enzon Pharmaceuticals reverse split before market open on Friday, April 3rd 2026.The 1-100 reverse split was announced on Friday, April 3rd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Energy Transfer (ET), BioCryst Pharmaceuticals (BCRX). Company Calendar Last Earnings5/04/2026Today9/20/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CIK727510 Webwww.enzon.com Phone(732) 980-4500Fax732-980-4585EmployeesN/AYear Founded1981Profitability EPS (Trailing Twelve Months)($6.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.41 million Net MarginsN/A Pretax Margin6.52% Return on Equity-21.54% Return on Assets-7.22% Debt Debt-to-Equity Ratio0.42 Current Ratio2.01 Quick Ratio1.16 Sales & Book Value Annual Sales$30 thousand Price / Sales107.59 Cash FlowN/A Price / Cash FlowN/A Book Value($3.40) per share Price / Book-1.28Miscellaneous Outstanding Shares742,000Free Float739,000Market Cap$3.23 million OptionableNot Optionable Beta-0.05 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:ENZN) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our PartnersMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredNew Form of AI Could Ignite the ‘Great Wealth Rotation’Marc Chaikin, a 60-year Wall Street veteran who worked alongside Paul Tudor Jones and Steve Cohen, says a new ...Chaikin Analytics | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...Banyan Hill Publishing | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enzon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENZN Stock Alerts